North America Pulmonary Embolism Therapeutics Market Size & Outlook, 2026-2034
North America Pulmonary Embolism Therapeutics Market Insights
- As highlighted in Reed Intelligence analysis, the North America Pulmonary Embolism Therapeutics Market, valued at USD 1500.25 Million in 2025, is estimated to achieve USD 2991.2 Million by 2034.
- The market is estimated to grow at a CAGR of 7.89% spanning 2026 to 2034.
- By market size, Anticoagulants led the Drug Class category in 2025.
- The Drug Class segment led by Thrombolytics is estimated to post the fastest growth, sustaining its position as the most lucrative during the forecast timeframe.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- North America represented 39.48% of the global Pulmonary Embolism Therapeutics Market size in 2025.
- By 2034, United States is estimated to hold the largest position in the global market in terms of size.
- Canada is estimated to remain the fastest-growing market in North America, advancing to USD 619.12 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 1500.25 Million |
| Market Size In 2034 | USD 2991.2 Million |
| Largest segment | Anticoagulants |
| Units | Revenue in USD Million |
| CAGR | 7.89% (2026-2034) |
| Segmnetation Covered | |
| North America |
|
| Drug Class |
|
| Route of Administration |
|
| End-Use |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
North America Pulmonary Embolism Therapeutics Market Country 2026-2034 (USD Million)
| North America | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | XX.x | XX.x | XX.x | 1192.84 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Canada | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
North America Pulmonary Embolism Therapeutics Market Drug Class 2026-2034 (USD Million)
| Drug Class | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anticoagulants | XX.x | XX.x | XX.x | 675.26 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Thrombolytics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
North America Pulmonary Embolism Therapeutics Market Route of Administration 2026-2034 (USD Million)
| Route of Administration | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oral | XX.x | XX.x | XX.x | 826.18 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Injectable | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
North America Pulmonary Embolism Therapeutics Market End-Use 2026-2034 (USD Million)
| End-Use | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 730.32 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Ambulatory Surgical Centers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Specialty Clinics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
